- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02138162
A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men
A Phase 1, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Enzalutamide in Male Subjects With Severe Hepatic Impairment and Normal Hepatic Function
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Screening takes place between Day -22 and Day -2, and subjects are admitted to the clinic on Day -1. Each subject receives a single oral dose of enzalutamide on Day 1, under fasted conditions. They are discharged on Day 7; ambulant visits take place until Day 50. An End of Study Visit (ESV) occurs 7-10 days after the last PK sampling or early withdrawal.
Full PK profiles are obtained for enzalutamide, metabolite 1 of enzalutamide (M1) and metabolite 2 of enzalutamide (M2) up to 1176 hours (Day 50) after administration.
Safety assessments are performed throughout the study. For subjects with severe hepatic impairment, additional Child-Pugh classification and laboratory safety tests (including liver function tests) are performed regularly after administration.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Sofia, Bulgaria, 1612
- Comac Medical Ltd.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control starting at Screening and continue throughout the study period and for 90 days after the final study drug administration.
- Male subject must not donate sperm starting at Screening and throughout the study period and for 90 days after the final study drug administration.
- Subject has a Body Mass Index (BMI) range of 18.5 - 34.0 kg/m2 inclusive. The subject weighs at least 50 kg [at Screening].
Inclusion Criteria:Subjects with severe hepatic impairment must also meet the following inclusion criteria:
- Subject has a Child-Pugh classification Class C (severe, 10 to 15 points).
Inclusion Criteria: For Healthy Subjects Only:
- Age- and BMI-matched to subjects with severe liver hepatic impairment.
Exclusion Criteria:
- Subject has known or suspected hypersensitivity to enzalutamide, or any components of the formulation used.
- Subject has history of seizure or any condition that may predispose to seizure. Also history of loss of consciousness or transient ischemic attack within 12 months of enrollment (Day 1 visit).
- Subject has used grapefruit (or grapefruit containing products) or marmalade in the week prior to admission to the clinical unit (Day -1), as reported by the subject.
Exclusion Criteria: For Healthy Subjects Only:
- Subject has any of the liver function tests above the upper limit of normal.
Exclusion Criteria: Subjects with severe hepatic impairment must also not have any of the following characteristics:
- Subject has fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within the screening period.
- Subject has surgical porto-systemic shunts, including TIPSS (Trans-jugular intrahepatic portosystemic shunt).
- Subject has presence of severe hepatic encephalopathy (grade > 2).
- Subject has advanced ascites.
- Subject has esophageal variceal bleeding in the medical history (within 6 months before Day -1).
- Subject has thrombocyte level below 40x109 /L and /or hemoglobin below 90 g/L.
- Subject has significant renal dysfunction (creatinine clearance below 50 mL/min, estimated according to the method of Modification of Diet in Renal Disease (MDRD) formula).
- Subject has had previous liver transplantation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1:Single dose of enzalutamide in hepatically impaired subjects
Single dose of enzalutamide
|
oral
Other Names:
|
Experimental: 2:Single dose of enzalutamide in healthy subjects
Single dose of enzalutamide
|
oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK) of enzalutamide after a single oral dose
Time Frame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
|
area under the plasma concentration - time curve (AUC) extrapolated to infinity (AUC0-inf)
|
Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
|
PK of enzalutamide after a single oral dose
Time Frame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
|
maximum concentration (observed) (Cmax)
|
Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
|
PK of enzalutamide plus N-desmethyl enzalutamide (M2) after a single oral dose
Time Frame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
|
area under the plasma concentration - time curve (AUC) extrapolated to infinity (AUC0-inf)
|
Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
|
PK of enzalutamide plus N-desmethyl enzalutamide (M2) after a single oral dose
Time Frame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
|
maximum concentration (observed) (Cmax)
|
Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK of enzalutamide, M1, M2 and the sum of enzalutamide plus N-desmethyl enzalutamide (M2)
Time Frame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
|
Cmax and AUC0-inf (M1, M2 only), time to attain Cmax (tmax), AUC up to last quantifiable concentration (AUC0-last), apparent terminal elimination half life (t1/2), apparent volume of distribution during the terminal phase after extra vascular dosing (Vz/F), apparent total body clearance after extra vascular dosing (CL/F) (parent compound only), Metabolite-to-Parent Ratio (MPR), percent extrapolated for AUC0-inf (%AUC)
|
Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
|
Additional pharmacokinetic variables for enzalutamide, and, as appropriate, for M1 and M2, based upon unbound plasma concentrations
Time Frame: Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
|
Unbound Cmax (Cmax,u), unbound AUC0-inf (AUC0-inf,u), and unbound AUC0-last (AUC0-last,u).
Unbound CL/F (CLu/F) and unbound Vz/F (Vz,u/F) (parent only)
|
Days 1-6, 8, 12, 15, 19, 22, 26, 29, 36, 43, 50
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9785-CL-0404
- 2012-004858-29 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Hepatic Impairment
-
PfizerRecruitingHealthy Volunteers | Moderate Hepatic Impairment | Severe Hepatic ImpairmentUnited States
-
Bausch Health Americas, Inc.TerminatedSevere Hepatic ImpairmentUnited States
-
EQRx International, Inc.CompletedSevere Hepatic ImpairmentUnited States
-
PfizerCompleted
-
TakedaCompletedSevere Hepatic ImpairmentUnited States
-
Mitsubishi Tanabe Pharma CorporationCompletedHealthy | Severe Hepatic ImpairmentCzechia, Hungary, Slovakia
-
GenfitCompletedLiver Diseases | Moderate Hepatic Impairment | Severe Hepatic ImpairmentUnited States
-
GlycoMimetics IncorporatedCompletedModerate Hepatic Impairment | Normal Hepatic FunctionUnited States
-
Agios Pharmaceuticals, Inc.CompletedModerate Hepatic ImpairmentUnited States
-
Merck Sharp & Dohme LLCCompletedModerate Hepatic ImpairmentUnited States
Clinical Trials on enzalutamide
-
ESSA PharmaceuticalsRecruitingProstate CancerCanada, United States, Australia
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedProstate Cancer | Pharmacokinetics of EnzalutamideUnited States
-
Radboud University Medical CenterActive, not recruitingProstatic Neoplasms, Castration-ResistantNetherlands
-
Groupe Hospitalier Pitie-SalpetriereCompletedEpilepsy | Prostate Cancer | Neuropathy | EncephalopathyFrance
-
Andreas JosefssonGöteborg University; Umeå University; Sahlgrenska University Hospital, Sweden; Sundsvall... and other collaboratorsTerminated
-
Hinova Pharmaceuticals Inc.CompletedMetastatic Castration Resistant Prostate CancerChina
-
Macquarie University, AustraliaUnknown
-
Fundación Canaria de Investigación SanitariaHospital Universitario de CanariasUnknown
-
Translational Research Center for Medical Innovation...Kagawa UniversityCompleted
-
Alessa Therapeutics Inc.National Cancer Institute (NCI)Not yet recruitingProstate AdenocarcinomaUnited States